MYMX: AI 评分 47/100 — AI 分析 (4月 2026)

Mymetics Corporation is a Swiss vaccine company focused on developing vaccines for infectious diseases. Their pipeline includes vaccine candidates for HIV-1/AIDS, Covid-19, influenza, RSV, malaria, and chikungunya.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Mymetics Corporation, a Swiss biotechnology company founded in 1990, specializes in the research and development of virosome-based vaccines targeting infectious and life-disabling diseases. With a diverse product pipeline including HIV-1/AIDS and malaria, the company operates in a competitive landscape, collaborating with research institutions and pharmaceutical companies to advance its vaccine candidates.

MYMX是做什么的？

Mymetics Corporation, originally named ICHOR Corporation, was founded in 1990 and rebranded in July 2001. Headquartered in Epalinges, Switzerland, the company is dedicated to the research and development of innovative vaccines designed to combat infectious and life-disabling diseases. Mymetics employs a virosome-based technology platform to develop its vaccine candidates. The company's product pipeline encompasses a range of vaccines targeting critical global health challenges, including HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. Mymetics actively engages in collaborative partnerships to advance its research and development efforts. These collaborations include agreements with the Texas Biomedical Research Institute, PATH Malaria Vaccine Initiative, and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, focusing on the development of virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate. Additionally, Mymetics collaborates with Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. Mymetics operates within the biotechnology sector, focusing on preventative medicine through vaccine development. The company's strategy involves both internal research and external collaborations to expand its pipeline and accelerate the development of its vaccine candidates.

MYMX的投资论点是什么？

Mymetics Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on virosome-based vaccine development for diseases like HIV-1/AIDS and malaria addresses significant unmet medical needs. However, the company's small market capitalization and negative profitability highlight its dependence on successful clinical trials and future partnerships. Key value drivers include the advancement of its vaccine candidates through clinical trials and securing partnerships with larger pharmaceutical companies. The success of these vaccines could lead to substantial revenue generation and increased market capitalization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. Investors should closely monitor the progress of Mymetics' clinical trials and partnership developments to assess the company's potential for long-term growth.

MYMX在哪个行业运营？

Mymetics Corporation operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The global vaccine market is projected to reach billions of dollars by 2026, driven by increasing awareness of preventative healthcare and the emergence of new infectious diseases. Mymetics focuses on virosome-based vaccines, a technology that offers potential advantages in terms of immunogenicity and safety. The company competes with larger pharmaceutical companies and specialized biotechnology firms, requiring strategic partnerships and successful clinical trials to gain market share.

Biotechnology

Healthcare

MYMX有哪些增长机遇？

Advancement of HIV-1/AIDS Vaccine Candidate: The global HIV vaccine market represents a significant opportunity. According to UNAIDS, approximately 39 million people were living with HIV in 2022. Successful development and commercialization of an effective HIV vaccine could generate substantial revenue for Mymetics. The timeline for this growth opportunity depends on the successful completion of clinical trials, which could take several years.
Development of Malaria Vaccine: Malaria remains a major global health challenge, particularly in developing countries. Mymetics' collaboration with the PATH Malaria Vaccine Initiative and other research institutions positions it to potentially develop a transmission-blocking malaria vaccine. The global malaria vaccine market is projected to grow, driven by the need for effective prevention strategies. Clinical trials and regulatory approvals will determine the timeline for this opportunity.
Expansion of Influenza Vaccine Portfolio: Mymetics is exploring the immunogenicity of influenza vaccines through a collaboration with Sanofi Pasteur Biologics, LLC. The seasonal influenza vaccine market is well-established, but there is a continuous need for improved vaccines with broader protection and enhanced efficacy. Mymetics' virosome-based technology could offer advantages in this area. The timeline depends on the results of ongoing research and development efforts.
Commercialization of Covid-19 Vaccine: While the initial surge in demand for Covid-19 vaccines has subsided, there remains a need for updated vaccines that address emerging variants. Mymetics' Covid-19 vaccine candidate could potentially address this need, particularly if it demonstrates superior efficacy or safety compared to existing vaccines. The timeline for this opportunity depends on the evolving dynamics of the pandemic and the regulatory approval process.
Partnerships and Licensing Agreements: Mymetics can pursue growth by forming strategic partnerships with larger pharmaceutical companies to co-develop and commercialize its vaccine candidates. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The timeline for this growth opportunity depends on Mymetics' ability to attract and secure favorable partnership agreements.

Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
Negative P/E ratio of -0.02 reflects the company's current lack of profitability.
Profit margin of -160166.7% indicates substantial losses relative to revenue.
Gross margin of -47966.7% suggests high cost of goods sold or significant research and development expenses.
Beta of 2.29 indicates higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.

MYMX提供哪些产品和服务？

Researches and develops vaccines for infectious diseases.
Focuses on virosome-based vaccine technology.
Develops vaccine candidates for HIV-1/AIDS.
Develops vaccine candidates for Covid-19.
Develops vaccine candidates for influenza.
Develops vaccine candidates for respiratory syncytial virus (RSV).
Develops vaccine candidates for malaria.
Develops vaccine candidates for chikungunya.

MYMX如何赚钱？

Develops vaccine candidates through internal research and development.
Collaborates with research institutions and pharmaceutical companies.
Seeks partnerships and licensing agreements to commercialize its vaccines.
Generates revenue through grants, partnerships, and potential future vaccine sales.

Governmental health organizations (e.g., WHO, national health ministries).
Non-profit organizations focused on global health (e.g., PATH, Bill & Melinda Gates Foundation).
Pharmaceutical companies seeking to expand their vaccine portfolios.
Patients in need of preventative vaccines.

Virosome-based vaccine technology platform.
Collaborative partnerships with research institutions and pharmaceutical companies.
Intellectual property protection for its vaccine candidates.
Focus on addressing unmet medical needs in infectious diseases.

什么因素可能推动MYMX股价上涨？

Upcoming: Clinical trial results for HIV-1/AIDS vaccine candidate.
Upcoming: Partnership announcements with pharmaceutical companies.
Upcoming: Regulatory submissions for vaccine approvals.
Ongoing: Research and development progress on malaria vaccine.
Ongoing: Collaboration with Sanofi Pasteur Biologics on influenza vaccine.

MYMX的主要风险是什么？

Potential: Clinical trial failures for vaccine candidates.
Potential: Regulatory delays or rejections.
Potential: Competition from established pharmaceutical companies.
Ongoing: Limited financial resources.
Ongoing: Dependence on successful partnerships.

MYMX的核心优势是什么？

Virosome-based vaccine technology platform.
Diverse vaccine pipeline targeting multiple infectious diseases.
Collaborative partnerships with research institutions.
Focus on addressing unmet medical needs.

MYMX的劣势是什么？

Limited financial resources.
Small number of employees.
Dependence on successful clinical trials.
Lack of commercialized products.

MYMX有哪些机遇？

Securing partnerships with larger pharmaceutical companies.
Advancing vaccine candidates through clinical trials.
Expanding vaccine pipeline to address emerging infectious diseases.
Obtaining regulatory approvals for its vaccines.

MYMX面临哪些威胁？

Clinical trial failures.
Regulatory hurdles.
Competition from established pharmaceutical companies.
Intellectual property challenges.

MYMX的竞争对手是谁？

Arcturus Therapeutics Holdings Inc. — Focuses on mRNA medicines. — (ACUS)
AOBiome, Inc. — Develops microbiome-based therapies. — (AOBI)
Apeiron Investment Group Ltd — Diversified investment company. — (APYI)
Cadexomer Iodine Inc. — Specializes in wound care products. — (CDXI)
Invesco Shipping ETF — Shipping industry ETF, not a direct competitor in vaccine development. — (ISHI)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Ronald Kempers
Headquarters: Epalinges, CH
Employees: 2
Founded: 1999

AI Insight

AI analysis pending for MYMX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Mymetics Corporation do?

Mymetics Corporation is a Swiss biotechnology company focused on the research and development of virosome-based vaccines for infectious and life-disabling diseases. The company's product pipeline includes vaccine candidates for HIV-1/AIDS, Covid-19, influenza, RSV, malaria, and chikungunya. Mymetics collaborates with research institutions and pharmaceutical companies to advance its vaccine candidates through preclinical and clinical development, aiming to address significant unmet medical needs in global health.

What do analysts say about MYMX stock?

As of March 16, 2026, there is no available analyst coverage or consensus for Mymetics Corporation (MYMX). The company's small market capitalization and OTC listing may limit analyst interest. Investors should conduct their own due diligence and consider the company's financial performance, clinical trial progress, and partnership developments when evaluating MYMX. Key valuation metrics are difficult to assess due to the company's negative profitability.

What are the main risks for MYMX?

Mymetics Corporation faces several key risks inherent to the biotechnology industry and its specific circumstances. Clinical trial failures represent a significant risk, as the success of its vaccine candidates is crucial for future revenue generation. Regulatory hurdles and delays in obtaining approvals can also impact the company's timeline and financial performance. Competition from larger pharmaceutical companies with greater resources poses a threat. Furthermore, the company's limited financial resources and dependence on partnerships create additional risks.